Inhibrx targets OX40 agonist-cancer vaccine studies from early next year

Inhibrx Biosciences says its latest mid-stage results show the potential of its OX40 agonist in immunogenic cancers — but also its prospects in combination with cancer vaccines in tumors with lower immunogenicity. “The next step for ...